Seratrodast
Seratrodast is a thromboxane A2 receptor antagonist used for the treatment of asthma in Japan and some Asian countries, where it reduces bronchoconstriction and airway inflammation mediated by thromboxane A2. By blocking thromboxane A2 prostanoid (TP) receptors on airway smooth muscle and inflammatory cells, it inhibits bronchoconstriction, platelet aggregation, and inflammatory cell recruitment. It provides anti-asthmatic effects without the direct bronchodilatory action of beta-agonists.
Molekularmasse
354,4000 g/mol
LogP
4,40
TPSA
71,40 Ų
Lipinski-Regel der Fünf
Bestanden
Wirkmechanismus
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CC1=C(C)C(=O)C(C(CCCCCC(=O)O)c2ccccc2)=C(C)C1=O
InChI
InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)
Molecular Formula
C22H26O4
HBD / HBA
1 / 4
Rotierbare Bindungen
8
Schwere Atome
26
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
Seratrodast is a thromboxane A2 receptor antagonist used for the treatment of asthma in Japan and some Asian countries, where it reduces bronchoconstriction and airway inflammation mediated by thromboxane A2. By blocking thromboxane A2 prostanoid (TP) receptors on airway smooth muscle and inflammatory cells, it inhibits bronchoconstriction, platelet aggregation, and inflammatory cell recruitment. It provides anti-asthmatic effects without the direct bronchodilatory action of beta-agonists.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Seratrodast is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL70972. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2449. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="seratrodast"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/seratrodast/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/seratrodast/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/seratrodast/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="seratrodast"></drugfyi-drug>